{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:48:09Z","timestamp":1792813689959,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eururo.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:26:30Z","timestamp":1757766390000},"page":"260-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Ken","family":"Herrmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2691-8421","authenticated-orcid":false,"given":"Steven","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"\u00d3Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Machaba","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Tempany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-3786","authenticated-orcid":false,"given":"Anders S.","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.08.005_b0005","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.08.005_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.005_b0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","article-title":"EAU-EANM Consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy","volume":"5","author":"Fanti","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.08.005_b0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.09.003","article-title":"European Association of Nuclear Medicine Focus 5: consensus on molecular imaging and theranostics in prostate cancer","volume":"85","author":"Oprea-Lager","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","article-title":"Purposeful sampling for qualitative data collection and analysis in mixed method implementation research","volume":"42","author":"Palinkas","year":"2015","journal-title":"Adm Policy Ment Health"},{"key":"10.1016\/j.eururo.2025.08.005_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eururo.2025.08.005_b0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ebnurs-2020-103303","article-title":"What are Delphi studies?","volume":"23","author":"Barrett","year":"2020","journal-title":"Evid Based Nurs"},{"key":"10.1016\/j.eururo.2025.08.005_b0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi technique in health sciences: a map","volume":"8","author":"Niederberger","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.eururo.2025.08.005_b0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: how to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J Methodol"},{"key":"10.1016\/j.eururo.2025.08.005_b0055","series-title":"The Rand\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001"},{"key":"10.1016\/j.eururo.2025.08.005_b0060","unstructured":"Microsoft Corporation. Microsoft Excel. 2018. https:\/\/office.microsoft.com\/excel."},{"key":"10.1016\/j.eururo.2025.08.005_b0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.08.005_b0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2024.08.022","article-title":"VISION: an individual patient data meta-analysis of randomised trials comparing magnetic resonance imaging targeted biopsy with standard transrectal ultrasound guided biopsy in the detection of prostate cancer","volume":"87","author":"Kasivisvanathan","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0075","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","article-title":"PI-RADS prostate imaging \u2013 Reporting and data system: 2015, version 2","volume":"69","author":"Weinreb","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0085","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","article-title":"[68Ga]Ga-PSMA versus [18F]PSMA positron emission tomography\/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature","volume":"5","author":"Evangelista","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.08.005_b0095","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1200\/JCO.18.01927","article-title":"Strategies for evaluation of novel imaging in prostate cancer: putting the horse back before the cart","volume":"37","author":"Vapiwala","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.08.005_b0100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-pair comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0115","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.005_b0120","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.005_b0125","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2967\/jnumed.120.251447","article-title":"Matched-pair comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET\/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor-related uptake and tumor positivity","volume":"62","author":"Kroenke","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0130","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2967\/jnumed.120.258574","article-title":"Matched\u2010pair comparison of 18F\u2010DCFPyL PET\/CT and 18F\u2010PSMA\u20101007 PET\/CT in 240 prostate cancer patients: inter\u2010reader agreement and lesion detection rate of suspected lesions","volume":"62","author":"Wondergem","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0135","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102289","article-title":"Incidence and survival of patients with prostate cancer in North-Rhine Westphalia, Germany","volume":"23","author":"Karpinski","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2025.08.005_b0145","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.005_b0150","doi-asserted-by":"crossref","unstructured":"Karpinski MJ, Rahbar K, B\u00f6gemann M, et al. Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.017.","DOI":"10.1016\/j.eururo.2025.04.017"},{"key":"10.1016\/j.eururo.2025.08.005_b0155","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1200\/JCO.2025.43.16_suppl.5011","article-title":"Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)","volume":"43","author":"Emmet","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.08.005_b0160","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0165","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2025.08.005_b0170","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233460","article-title":"Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)","volume":"312","author":"Kuo","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2025.08.005_b0175","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.08.005_b0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0190","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2967\/jnumed.123.266164","article-title":"Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database","volume":"65","author":"Emmett","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0200","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2023.11.008","volume":"7","author":"Buteau","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.08.005_b0205","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2022.10.005","article-title":"More accurate imaging is not stage migration: time to move from \u201chubble\u201d to \u201cwebb\u201d in hormone-sensitive prostate cancer","volume":"83","author":"Ayati","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.005_b0215","first-page":"1054","article-title":"Evidence-based clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer using real-world data","volume":"66","author":"Unterrainer","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0220","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11934-023-01174-5","article-title":"Stereotactic body radiation therapy salvage for lymph node recurrent prostate cancer in the era of PSMA PET Imaging","volume":"24","author":"Hayek","year":"2023","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2025.08.005_b0225","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/pros.24579","article-title":"PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET\/CT within a prospective study","volume":"83","author":"Francolini","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.08.005_b0230","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.7150\/thno.44584","article-title":"Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with 68Ga-PSMA-11-PET","volume":"10","author":"Ferraro","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.eururo.2025.08.005_b0235","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA Ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0240","unstructured":"Research4Life. 68Ga PET\/CT | PET\/MR \u2013 EANM EARL. https:\/\/earl.eanm.org\/68ga-pet-ct-mr\/."},{"key":"10.1016\/j.eururo.2025.08.005_b0245","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2967\/jnumed.117.195255","article-title":"Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0","volume":"59","author":"Rowe","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0250","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2025.08.005_b0255","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2025.08.005_b0260","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825004828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825004828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:30:48Z","timestamp":1771615848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825004828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0302283825004828"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.08.005","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}